132 related articles for article (PubMed ID: 15173889)
1. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens.
Yu XZ; Albert MH; Martin PJ; Anasetti C
J Clin Invest; 2004 Jun; 113(11):1624-30. PubMed ID: 15173889
[TBL] [Abstract][Full Text] [Related]
2. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.
Zeng M; Guinet E; Nouri-Shirazi M
Transpl Immunol; 2009 Dec; 22(1-2):82-92. PubMed ID: 19635560
[TBL] [Abstract][Full Text] [Related]
4. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
5. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
6. Control of mouse graft-versus-host disease following allogeneic bone marrow transplantation by blocking the CD28/B7 signaling pathway with lentiviral vector-mediated RNA interference.
Sang W; Zhou C; Cheng N; Li Z; Zeng L; Xu K
Immunol Lett; 2011 May; 136(2):194-202. PubMed ID: 21277900
[TBL] [Abstract][Full Text] [Related]
7. Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.
Tellander AC; Pettersson U; Runström A; Andersson M; Michaëlsson E
J Autoimmun; 2001 Aug; 17(1):39-50. PubMed ID: 11488636
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
9. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
10. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.
Saito K; Sakurai J; Ohata J; Kohsaka T; Hashimoto H; Okumura K; Abe R; Azuma M
J Immunol; 1998 May; 160(9):4225-31. PubMed ID: 9574523
[TBL] [Abstract][Full Text] [Related]
11. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
Khattri R; Auger JA; Griffin MD; Sharpe AH; Bluestone JA
J Immunol; 1999 May; 162(10):5784-91. PubMed ID: 10229811
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
Zhu ZX; Fan LY; Wang Q
Eur Surg Res; 2011; 46(3):109-17. PubMed ID: 21242693
[TBL] [Abstract][Full Text] [Related]
13. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
15. Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD.
Fujimura J; Takeda K; Kaduka Y; Saito M; Akiba H; Yagita H; Yamashiro Y; Shimizu T; Okumura K
Pediatr Transplant; 2010 Jun; 14(4):540-8. PubMed ID: 20136724
[TBL] [Abstract][Full Text] [Related]
16. Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells.
Barbon CM; Davies JK; Voskertchian A; Kelner RH; Brennan LL; Nadler LM; Guinan EC
Am J Transplant; 2014 Feb; 14(2):305-18. PubMed ID: 24410845
[TBL] [Abstract][Full Text] [Related]
17. In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease.
Hartmann N; Leithäuser F; Albers C; Duyster J; Möller P; Debatin KM; Strauss G
Leukemia; 2011 May; 25(5):848-55. PubMed ID: 21331071
[TBL] [Abstract][Full Text] [Related]
18. In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.
Soloviova K; Puliaiev M; Haas M; Via CS
J Immunol; 2013 May; 190(9):4562-72. PubMed ID: 23526821
[TBL] [Abstract][Full Text] [Related]
19. Costimulatory blockade induces hyporesponsiveness in T cells that recognize alloantigen via indirect antigen presentation.
Phillips NE; Greiner DL; Mordes JP; Rossini AA
Transplantation; 2006 Oct; 82(8):1085-92. PubMed ID: 17060858
[TBL] [Abstract][Full Text] [Related]
20. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
